Market Overview

UPDATE: Stifel Nicolaus Initiates Oncolytics Ciotech at Buy with $6 PT on Reolysin Cancer Focus

Related ONCY
Oncolytics Biotech Announces Phase 1b Study in Advanced Pancreatic Cancer is Now Active
Oncolytics Biotech Collaborators to Present Survival Data from REO 016 Study in NCLC at IASLC

Stifel Nicolaus initiated its coverage on Oncolytics Ciotech (NASDAQ: ONCY) with a Buy rating and a price target of $6 a share.

Stifel Nicolaus commented, "We view ONCY's sole clinical candidate Reolysin as a compelling potential treatment for ~60% of cancers. Reolysin is a specific strain of a naturally occurring virus that only replicates in cancer cells with an activated Ras signaling pathway, a key metabolic pathway in cell metabolism that is mutated in over 60% of all carcinomas. Reolysin has demonstrated compelling efficacy in numerous oncology indications and as a live virus Reolysin's main side effect is "viral syndrome", not the typical side effects of chemotherapy."

Oncolytics Ciotech closed at $2.76 on Wednesday.

Latest Ratings for ONCY

Sep 2013NeedhamInitiates Coverage onBuy
Mar 2013PiperJaffrayInitiates Coverage onOverweight
Dec 2012Bloom Burton & Co.DowngradesBuyHold

View More Analyst Ratings for ONCY
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (ONCY)

View Comments and Join the Discussion!